Dalfampridine in Primary Lateral Sclerosis — The Cornell Trial and Cerebellar Purkinje Cell Mechanism
Dalfampridine — the extended-release formulation of 4-aminopyridine (4-AP), FDA-approved for walking impairment in multiple sclerosis — has a dual mechanism that makes it an unusually well-matched candidate for PLS. It rescues conduction in demyelinated or dysfunctional upper motor neuron axons, as it does in MS. But it also directly enhances the output precision of cerebellar Purkinje cells — exactly the cells whose function many PLS patients depend on as a compensatory walking circuit when corticospinal drive is degraded. The Weill Cornell open-label trial tested dalfampridine in PLS and UMN-predominant ALS walking impairment, and the Kalla/Glasauer research from 2007 provides the clearest mechanistic account of what 4-AP does inside the cerebellum to make this possible.
What they did
The Cornell Trial (NCT02868567)
Investigators at Weill Medical College of Cornell University enrolled 35 subjects with either confirmed primary lateral sclerosis or upper-motor-neuron-predominant ALS — patients in whom walking impairment was driven by corticospinal tract dysfunction rather than lower motor neuron weakness. The trial ran for 18 weeks as an open-label safety and tolerability study, a design appropriate for a drug already known to be safe in MS but not yet tested in PLS or UMN-ALS populations.
The primary outcome measure was the Timed 25-Foot Walk (T25FW), a validated functional ambulation test that asks the patient to walk a 25-foot course as quickly as safely possible. The T25FW is the same measure used in dalfampridine's pivotal MS trials, which makes the Cornell results directly comparable to the MS evidence base. Baseline T25FW was measured before any treatment, and then repeated at weeks 2, 4, 6, 10, 14, and 18 while patients were on medication.
The investigators defined a "consistent responder" as any subject who showed improvement on the T25FW in at least 3 of the 4 on-medication assessments compared with baseline. This responder definition deliberately mirrors the one used in the MS Phase 3 dalfampridine trials (the Goodman 2009 and 2010 studies), allowing a direct comparison of response rates across disease populations. As of 2026, full peer-reviewed results of NCT02868567 had not been published in a journal article; the trial design and registration are documented at ClinicalTrials.gov.
The Kalla/Glasauer Cerebellar Research (Brain 2007)
In parallel with the clinical interest in dalfampridine for walking, Kalla, Glasauer and colleagues at the German Center for Vertigo and Balance Disorders were investigating why 4-aminopyridine works so well for cerebellar oculomotor disorders — specifically downbeat nystagmus, an involuntary downward drift of the eyes caused by cerebellar dysfunction. Their 2007 paper in Brain tested 4-AP in patients with cerebellar atrophy and downbeat nystagmus, measuring gaze-holding accuracy and neural integrator function with quantitative oculomotor recordings.
The mechanistic question they pursued was specific: how does a potassium channel blocker restore the precision of a neural computation that should depend on the integrity of Purkinje cell pacemaking? They found that the eye movement improvement in their patients was greatest in those with predominantly cerebellar atrophy — the subgroup with the most compromised Purkinje cell output — and that the improvement was consistent with restoration of neural integrator function in the cerebellar flocculi, the region responsible for gaze-holding and vestibulo-ocular reflex calibration.
What they found
Walking Response in PLS and UMN-ALS
The Cornell trial design mirrors the MS responder framework, which established that approximately 42.9% of MS patients met the consistent responder criterion on dalfampridine versus 9.3% of placebo-treated patients. Among MS responders, average walking speed improved by approximately 24.7%. In the MS trials, this was not a diffuse, nonspecific effect: the consistent-responder methodology identified a biologically coherent subpopulation that responded durably and substantially. The Cornell trial was designed specifically to determine whether a comparable responder subpopulation exists in PLS.
The open-label design — without a placebo comparator — limits the conclusions that can be drawn about efficacy. Placebo effects on timed walking tests are real and can reach 10–15% in conditions where patients know they are receiving active medication. However, the consistent-responder criterion, which requires improvement across multiple assessments rather than a single time point, substantially reduces the probability of a sustained placebo response meeting threshold. An open-label trial is appropriate and sufficient to establish that the drug is safe and tolerable in PLS, and to generate an initial responder rate estimate that would power a future placebo-controlled trial.
The Purkinje Cell Mechanism
Kalla and Glasauer's 2007 findings established the cellular mechanism with precision. 4-Aminopyridine blocks voltage-gated potassium channels — specifically Kv1 and Kv3 channel subtypes — on cerebellar Purkinje cell axons and somata. This prolongs the action potential, increases afterhyperpolarization precision, and restores the regularity of spontaneous pacemaking in cells whose pacemaking has been degraded by disease or degeneration.
Purkinje cells are the only output neurons of the cerebellar cortex. They fire spontaneously at 50–100 Hz in health, and this tonic inhibitory output controls the deep cerebellar nuclei, which in turn project to the thalamus and motor cortex. When Purkinje cell pacemaking becomes irregular — as it does in cerebellar atrophy, EA2, SCA subtypes, and potentially in compensatory use states where Purkinje cells are being driven harder than normal — their output degrades from a precise inhibitory control signal into a noisy one, and downstream motor coordination suffers accordingly.
4-AP's action restores precision at the Purkinje cell level. It does not rebuild lost neurons or reverse atrophy. It makes the surviving cells fire more reliably. In Kalla and Glasauer's patients, this was sufficient to meaningfully improve gaze-holding accuracy and reduce downbeat nystagmus — a direct functional readout of cerebellar output quality. The same mechanism, applied to the locomotor cerebellar circuits that gate stepping, timing, and trunk stabilization, predicts that walking would improve in patients whose walking depends on cerebellar compensation.
Subsequent work by Strupp, Kalla and colleagues confirmed and extended these findings across multiple cerebellar disorders. The use of aminopyridines for episodic ataxia type 2, downbeat nystagmus, and SCA-6 is now supported by multiple randomized trials and has entered clinical guidelines for neuro-otology in Germany and elsewhere. A 2016 mouse model paper in Scientific Reports demonstrated 4-AP's ability to improve ataxic gait in SCA-6 mice. A 2024 paper in eBioMedicine described clinical benefit of 4-AP in GAA-FGF14 disease, another channelopathy of Purkinje cell pacemaking. The mechanistic coherence across these applications is strong.
Why it matters
PLS patients lose their primary walking drive — the fast, powerful corticospinal motor command that initiates and maintains stride. The question is not whether this loss occurs, but how the remaining nervous system adapts. The compensatory circuits framework (discussed fully on the Targeting Compensatory Circuits page) identifies the cerebellum as a critical backup system: when corticospinal commands are degraded, cerebellar circuits that normally serve error correction and pattern stabilization are recruited more heavily. These circuits can, in many patients, support functional walking for years — but they are working harder than they were designed to, and their output is only as good as the precision of the Purkinje cell pacemaking that drives them.
This is where dalfampridine becomes more than an axonal conduction rescue drug. In PLS patients who are walking on compensatory cerebellar circuits, 4-AP restores exactly the precision that those overloaded Purkinje cells most need. The dual mechanism — rescuing both the damaged corticospinal axons (the primary pathway) and the overloaded cerebellar compensation (the backup pathway) — makes dalfampridine uniquely well-matched to the PLS pathophysiology in a way that no purely anti-spasticity drug can replicate.
For patients and families, this distinction matters practically. Anti-spasticity drugs (baclofen, tizanidine, cannabis) reduce the excess tone in the stiff, overactive muscles — they address a symptom. Dalfampridine, if the dual mechanism is correct, is trying to rescue function by improving the quality of the motor commands being generated — it addresses the underlying signal. These are complementary, not competing approaches.
The FDA approval for MS walking impairment establishes that dalfampridine is a real drug with a real evidence base and a real regulatory record. The off-label use in PLS is therefore a well-characterized off-label use — not an experimental guess — being tested in a defined clinical population at a leading academic center.
Limitations
The Cornell trial's open-label design is the primary limitation for efficacy conclusions. Without a placebo comparator, a consistent walking speed improvement cannot be definitively attributed to drug effect. This is the expected limitation of a Phase 2 open-label safety and tolerability study, and it is not a disqualifying weakness — it is the correct first step before a larger controlled trial. The fact that the consistent-responder methodology substantially reduces placebo response makes the limitation less severe than it would be for a single-assessment endpoint.
Full peer-reviewed publication of the Cornell trial results has not occurred as of 2026. The trial design, population, and outcome measures are registered at ClinicalTrials.gov (NCT02868567) and reflect genuine clinical research at a leading institution, but direct access to the quantitative results requires publication or contact with the investigators.
The Kalla/Glasauer mechanistic work was done in the context of oculomotor cerebellar circuits, not locomotor circuits. The flocculus and the vermis are both cerebellar, and Purkinje cells in both regions share the same pacemaking mechanism, but the circuits subserving gaze stabilization and the circuits subserving walking are distinct. The extrapolation from one to the other is mechanistically coherent but not directly demonstrated in the context of PLS.
How this connects
The Cornell trial and the Kalla/Glasauer mechanism are two of the central pieces of evidence behind the Targeting Compensatory Circuits framework for PLS treatment. That page brings together the cerebellar compensation hypothesis, the corticospinal reserve hypothesis, and the dopaminergic basal ganglia circuit hypothesis into a single mechanistic account of how the PLS nervous system reorganizes around the damaged upper motor neuron system — and what that reorganization implies for therapeutic targeting.
For the complementary cerebellar stabilization approach — a mechanism that works on the same Purkinje cells through a different pathway — see the acetazolamide cerebellar stabilization page. For the broader spasticity evidence base including oral and intrathecal agents, see the Spasticity Research Hub. The CANALS nabiximols trial covers cannabinoids as a complementary approach to spasticity management in the same patient population.
Citations
NCT02868567. A Pilot Study of Dalfampridine in Subjects With Primary Lateral Sclerosis or Upper Motor Neuron Predominant Amyotrophic Lateral Sclerosis. ClinicalTrials.gov. Sponsor: Weill Medical College of Cornell University. Registered 2016.
Kalla R, Glasauer S, Büttner U, Brandt T, Strupp M. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain. 2007;130(9):2441–2451. doi:10.1093/brain/awm172
Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732–738. doi:10.1016/S0140-6736(09)60442-6
Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77(3):269–275. doi:10.1212/WNL.0b013e3182267for